This review outlines the use of extracorporeal therapies in the treatment of sepsis and septic AKI, considering the classic aspects of extracorporeal renal replacement therapy including indications, timing, and delivered dose but also discussing the various techniques that are currently used to achieve immune homeostasis. The authors further discuss the evidence accumulated to date and suggest possibilities for the future treatment of this entity of patients. In this context, the CytoSorb therapy is mentioned as one of the most promising approaches, due to its improved biocompatibility and therefore the opportunity for whole blood hemoperfusion, its efficiency in removing multiple inflammatory mediators shown in animals studies as well as in case reports and due to its beneficial effects on chemokine gradients, which may restore chemokine gradients towards infected tissue and away from healthy organs through leukocyte trafficking control.
In addition to numerous prospective study projects CytoSorbents also has marketing experience in the context of larger case series from the indications of septic shock, cardiac surgery, lung transplantation, liver failure and others.
Upon completion of the retrospective analysis, we expect mid-2015 several publications.
The number of published reports on individual treatments is steadily growing and already covers a wide area of CytoSorb-applications. A selection of published and unpublished case reports can be found here:
ANZICS/ACCCN ASM 2015, 40th Annual Scientific Meeting of the Australia and New Zealand Intensive Care Society and Australian College of Critical Care Nurses is starting on 29 October, 2015 and ending on 31 October, 2015.
TekMed supply a complete range of Blood Purification Devices for the ICU.
• CytoSorb: an extracorporeal blood purification therapy designed to reduce excessive levels of inflammatory mediators such as cytokines, or “cytokine storm”, from blood. In doing so, the goal is to reduce the potentially deadly systemic inflammatory response syndrome (SIRS) seen in life-threatening inflammatory conditions. CytoSorb columns fit onto all CRRT machines in ANZ
• Infomed HF440 CRRT machines and kits
o Complete range of therapies
o Reduced “off treatment” time
o “no touch” waste handling
o Extended pressure mode for hookup to ECMO
• Vascular access catheters for CRRT
o FreeFlow 360° inlet – great flows
o SDL silicon 13.5 fr – non kink 15-32cm insertion lengths"
DIVI Research Award / Poster Competition
The DIVI sees itself as a scientific society and the scientific discussion would give a higher profile. Therefore we have created a new format to back as an abstract submitted work more at the center of the Congress and a higher monetary value.
The eight best abstracts will be selected by an assessment committee before Congress. The eight award winners will then at a symposium in front of a high-profile jury of experts against each other, each prize winner can present his work here as part of a fifteen-minute lecture. The expert jury selects the winners immediately after the symposium from, are being awarded for the winner #$%$ 2.000, the second #$%$ 1,500, the third #$%$ 1,000 and as for the places 4-8 per 500.- #$%$.
Another application is in cancer immunotherapy. CytoSorb® was specifically designed to treat "cytokine release syndrome (CRS)" or cytokine storm. We believe that it can be used as a rescue therapy, when patients develop uncontrolled CRS in activated T-cell or CAR T-cell cancer immunotherapy. Cancer cachexia is another potential opportunity. Cancer cachexia is a wasting condition that occurs in most cancers that leads to rapid uncontrolled weight loss, anorexia, and physical debilitation. Patients lose the physical reserve needed to tolerate treatment and fight the cancer. Because CytoSorb® can remove a broad range of cytokines and other inflammatory mediators that drive cancer cachexia, it may be very helpful in this condition. CytoSorbents is exploring this application, as well as the use of CytoSorb® as a primary cancer immunotherapy to kickstart the immune system to attack cancer, with researchers at the University of Pennsylvania School of Veterinary Medicine.
These hospitals have already registered for participation:
University Hospital Ulm
University Hospital Göttingen
University Hospital Rostock
University Hospital Greifswald
Ev. Hospital Bielefeld
University Hospital Oldenburg
Heart and Diabetes Center Bad Oeynhausen
University Hospital Hamburg-Eppendorf
University Hospital Essen
University Hospital Munich Rechts der Isar
University Hospital Düsseldorf
Hospital Barmherzige Brüder Munich
Hospital St. Elisabeth und St. Barbara Halle
Vivantes Hospital Berlin Neukölln
University Hospital Freiburg
St. Johannes Hospital Dortmund
Asklepios Hospital Hamburg
University Hospital Bergmannsheil Bochum
Agaplesion Hospital Rotenburg
Universitätsklinikum Schleswig-Holstein, Lübeck
Klinikum Region Hannover
Maria Hilf Klinik Mönchengladbach
University Hospital Zurich
Hospital Hietzing Vienna
University Hospital Innsbruck
Medizinische Universität Wien
University Hospital Szeged
University Hospital Debrecen
Semmelweis Universität, Budapest
VieCuri Medical Center Noord-Limburg
Ziekenhuis De Tongerschans, Heerenveen
Laurentius Ziekenhuis Roermond
ISALA-Klinik, Zwolle, NL
Erasme Hospital Brussels
Ain Shams University, Kairo
Fundeni Clinical Insitute Bucharest
University County Emergency Hospital Timi?oara
Emergency County Hospital Cluj
Muljibhai Patel Urological Hospital
Clinica de la Mujer, Bogotá
Cardio Center Pontika, Burgas
Harefield Hospital Middlesex
Nuovo Ospedale Civile Sant Agostino Estense, Modena
What is sepsis and why is it so dangerous?
Sepsis a severe health problem sparked by your body’s reaction to infection. When you get an infection, your body fights back, releasing chemicals into the bloodstream to kill the harmful bacteria or viruses. When this process works the way it is supposed to, your body takes care of the infection and you get better. With sepsis, the chemicals from your body’s own defenses trigger inflammatory responses, which can impair blood flow to organs, like the brain, heart or kidneys. This in turn can lead to organ failure and tissue damage.
The time for filing a petition for review of the initial decision in this proceeding has
expired. No such petition has been filed by AuraSound, Inc., C2C CrowdFunding, Inc.,
Convenience TV Inc., or NewMarket Technology, Inc., and the Commission has not chosen to
review the decision on its own initiative.
Accordingly, notice is hereby given, pursuant to Rule 360(d) of the Commission's Rules
of Practice,1 that the initial decision of the administrative law judge has become the final
decision of the Commission with respect to AuraSound, Inc., C2C CrowdFunding, Inc.,
Convenience TV Inc., and NewMarket Technology, Inc.
2 The order contained in that decision is hereby declared effective. The initial decision ordered that, pursuant to Section 12(j)
of the Securities Exchange Act of 1934, the registrations of each class of registered securities of
AuraSound, Inc., C2C CrowdFunding, Inc., Convenience TV Inc., and NewMarket Technology,
Inc., are revoked.
Lunch-Symposium, 10.09.2015, 12:00 – 13:30
SIRS and Sepsis – regain control with CytoSorb therapy
Chair: Weigand M, Heidelberg; Molnar Z, Szeged
How can CytoSorb modulate the excessive immune response?
Gerlach H, Berlin
Clinical results of a septic shock study
Molnar Z, Szeged
Use of CytoSorb® in patients with severe sepsis and septic shock - when
is it best to start?
Nierhaus A, Hamburg
The international CytoSorb registry – current status
Brunkhorst FM, Jena
Supported by Cytosorbents Europe GmbH
GEOMC Co., LTD. Took a Legal Action in Recovering the Inventory of the Scrambler Therapy Device in the US
SEOUL, South Korea, /PRNewswire/ -- GEOMC Co., LTD. announced today that it filed a Complaint in the United States District Court, District of Connecticut to take possession of the inventory of the Scrambler Therapy Device held by Competitive Technologies, Inc. ("CTTC" or "CTI"). The majority of the inventory has been secured under the UCC filing by GEOMC. CTI has refused to return the inventory in spite of GEOMC's repeated requests since 2013.